Results 31 to 40 of about 22,196 (255)

The Effect of Pretreatment with the Hydroalcoholic Extract of Ginger on the Modulation of Dopamine D2 Receptor Agonist and Antagonist Impacts on Pain Sensitivity in Male Rats

Herbal Medicines Journal, 2022
Background and Aim: Zingiber officinale (ginger) extract increased dopamine concentration in various brain areas. Therefore, the present study aimed to investigate how ginger extract can affect the efficiency of D2 receptor agonist (bromocriptine) and ...
Mohammad Hossein Faraji, Mahnaz Taherianfard *   +1 more
doaj   +1 more source

Bromocriptine treatment in patients with peripartum cardiomyopathy and right ventricular dysfunction

Clinical Research in Cardiology, 2018
BackgroundRight ventricular (RV) dysfunction predicts adverse outcome in peripartum cardiomyopathy (PPCM). We recently demonstrated beneficial effects associated with the prolactin release inhibitor bromocriptine at different doses when added to standard
A. Haghikia, J. Schwab, J. Vogel-Claussen, D. Berliner, T. Pfeffer, T. König, C. Zwadlo, V. Moulig, A. Franke, Marziel Schwarzkopf, P. Ehlermann, R. Pfister, G. Michels, R. Westenfeld, V. Stangl, U. Kühl, E. Podewski, I. Kindermann, M. Böhm, K. Sliwa, D. Hilfiker-Kleiner, J. Bauersachs   +21 more
semanticscholar   +1 more source

Circadian‐timed quick‐release bromocriptine lowers elevated resting heart rate in patients with type 2 diabetes mellitus

Endocrinology, Diabetes & Metabolism, 2020
Objective Sympathetic nervous system (SNS) overactivity is a risk factor for insulin resistance and cardiovascular disease (CVD). We evaluated the impact of bromocriptine‐QR, a dopamine‐agonist antidiabetes medication, on elevated resting heart rate (RHR)
Bindu Chamarthi, Aaron Vinik, Michael Ezrokhi, Anthony H. Cincotta   +3 more
doaj   +1 more source

Repositioning Dopamine D2 Receptor Agonist Bromocriptine to Enhance Docetaxel Chemotherapy and Treat Bone Metastatic Prostate Cancer

Molecular Cancer Therapeutics, 2018
Docetaxel resistance remains a major obstacle in the treatment of prostate cancer bone metastasis. In this study, we demonstrate that the dopamine D2 receptor (DRD2) agonist bromocriptine effectively enhances docetaxel efficacy and suppresses skeletal ...
Yang Yang, K. Mamouni, Xin Li, Yanhua Chen, S. Kavuri, Yuhong Du, H. Fu, O. Kucuk, Daqing Wu   +8 more
semanticscholar   +1 more source

Dopaminergic agonist bromocriptin in treatment of diabetes mellitus type 2

Ожирение и метаболизм, 2011
Bromocriptine is a sympatholytic agonist of dopamine receptors, which is now proposed for treatment of type 2 diabetes mellitus. In animal studies bromocriptine elevates the decreased levels of dopamine in hypothalamus and blocks excessive sympathetic ...
O A Gerasimenko, E Pigarova, L K Dzeranova   +2 more
doaj   +1 more source

The mode of action of bromocriptine [PDF]

FEBS Letters, 1981
1. Introduction Bromocriptine, an ergot alkaloid and dopamine agonist, is the treatment of choice for the induction of ovulation and pregnancy in cases of infertility due to both functional and organic hyperprolactinemia, the latter being due to prolactin secreting pituitary adenomas.
D. Weinstein, Joseph G. Schenker, R. Folman, J.H. Slonim, Avraham Hochberg, Nathan de-Groot, I. Gloger   +6 more
openaire   +3 more sources

Bromocriptine monotherapy overcomes prostate cancer chemoresistance in preclinical models

Translational Oncology, 2023
Chemoresistance is a major obstacle in the clinical management of metastatic, castration-resistant prostate cancer (PCa). It is imperative to develop novel strategies to overcome chemoresistance and improve clinical outcomes in patients who have failed ...
Lijuan Bai, Xin Li, Yang Yang, Rui Zhao, Elshaddai Z. White, Alira Danaher, Nathan J. Bowen, Cimona V. Hinton, Nicholas Cook, Dehong Li, Alyssa Y. Wu, Min Qui, Yuhong Du, Haian Fu, Omer Kucuk, Daqing Wu   +15 more
doaj  

Bromocriptine mesylate: Food and Drug Administration approved new approach in therapy of non-insulin dependant diabetes mellitus with poor glycemic control

Journal of Pharmacy and Bioallied Sciences, 2010
Food and Drug Administration (FDA) approved bromocriptine mesylate, a quick release formulation, 0.8 mg tablets, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Yogendra Keche
doaj   +1 more source

Severe Hypoglycemia Due To the Administration of Bromocriptine in a Non-Diabetic Patient: A Case Study

Case Reports in Clinical Practice, 2020
The patient was a 24-year-old man with persistent vegetative state following severe traumatic brain injury due to a car accident, who was referred to the emergency department with a generalized tonic-clonic seizure due to severe hypoglycemia. The patient
Saeed Choobkar, Samad Nazarpoor, Mojgan kaviani   +2 more
doaj   +1 more source

Clinical Presentation and Management of Mastalgia: A Cohort Study [PDF]

Journal of Clinical and Diagnostic Research, 2020
Introduction: Recurring mastalgia, non-cyclical mastalgia and nonspecific extra-mammary pain are usually categorised as breast pain. Aim: To determine the most usual aetiology of mastalgia and its response to management modalities like topical Non ...
TG Raghu
doaj   +1 more source